Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics AG’s D2000 Adsorption Cartridge has the potential to reduce the levels of inflammatory cytokines responsible for acute respiratory failure in Covid-19 patients. Credit: Terumo BCT, PR000.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Terumo BCT and Marker Therapeutics for blood purification device to treat acute respiratory failure in Covid-19 patients.

The authorisation has been given for the use of Terumo BCT’s Spectra Optia Apheresis System along with Marker Therapeutics’ Depuro D2000 Adsorption Cartridge.

This combination is indicated to treat Covid-19 patients aged 18 years or older with Covid-19, admitted to the intensive care unit (ICU), with confirmed or imminent respiratory failure.

Together the devices filter the blood and return it to the patient. This reduces the number of cytokines and other inflammatory mediators. Cytokines are active proteins in the bloodstream that control a cell’s immune response.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

These proteins, which are removed, are normally elevated during infections and are also associated with a ‘cytokine storm’ that occurs in some Covid-19 patients, causing severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

Marker Therapeutics chairman David Cohen said: “By combining our plasma adsorption cartridge with Terumo BCT’s technology, this partnership offers the potential to develop a unique global solution for treatment of acute respiratory failure in Covid-19.”

Terumo BCT and Marker Therapeutics collaborated to combine their existing technologies to offer this new approach to potentially treat severe respiratory symptoms caused by Covid-19.

Terumo BCT CEO and president Antoinette Gawin said: “The pace of this collaboration between the companies is incredible. We are leaving no stone unturned in exploring existing and new ways for our products to mitigate the impact of Covid-19.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact